Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
NAMS
#1222
NewAmsterdam Pharma Company N.V. Ordinary Shares
35.460
0
+5.00%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+5.00%
Monatliche Änderung
+9.89%
6 month change
-2.23%
Jahresänderung
-2.23%
Vorheriger Schlusskurs
33.770
0
Open
35.460
0
Bid
Ask
Low
35.460
0
High
35.460
0
Volumen
59
Märkte
Aktien
Gesundheitswesen
NAMS
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
92.39 M
109.82 M
112.27 M
112.63 M
113.39 M
114.98 M
—
Valuation ratios
Enterprise value
1.11 B
2.05 B
1.55 B
1.48 B
2.69 B
3.54 B
9.26 B
Price to earnings ratio
-7.38
-10.04
-11.13
-11.46
-14.15
-20.4
-57.13
Price to sales ratio
45.52
53.22
40.94
28.37
86.95
184.61
340.87
Price to cash flow ratio
-9.52
-15.29
-14.26
-15.52
-21.71
-28.11
-79.59
Price to book ratio
1.01
3.2
0.89
0.71
1.03
6.08
8.71
Enterprise value to EBITDA ratio
—
-10.6
—
—
-12.17
-14.24
—
Profitability ratios
Return on assets %
0.04
0.11
0.05
0.02
0.09
0.1
0.26
Return on equity %
0.04
0.12
0.05
0.02
0.1
0.11
0.28
Return on invested capital %
301.17
—
—
—
259.21
450.78
—
Gross margin %
100
63.69
-96.14
77.6
-816.95
-31.09 K
-31.92 K
Operating margin %
85.89
338.47
2 314.47
186.13
15.85 K
206.19 K
224.53 K
EBITDA margin %
—
-374.38
-2 508.87
-208.3
-16.74 K
-237.19 K
-256.65 K
Net margin %
57.18
721.71
1 327.3
90.7
20.69 K
234.13 K
256.24 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
10.61
8.08
19.98
21.08
12.57
7.88
61.51
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.02
0
0.02
0
0
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.13
0.4
0.31
0.32
0.28
0.35
1.25
EBIT per share
—
-0.51
-0.64
-0.34
-0.49
-0.64
-2.11
EBITDA per share
—
-0.51
-0.64
-0.34
-0.49
-0.64
-2.11
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.46
8.18
6.96
6.23
5.91
5.37
24.48
Net current asset value per share
4.62
9.15
7.04
6.49
6.15
5.71
25.39
Tangible book value per share
3.99
8.02
6.69
6.56
6.11
5.77
25.13
Working capital per share
4.19
8.02
6.69
6.19
5.66
4.98
23.52
Book value per share
4
8.03
6.69
6.57
6.12
5.77
25.15
Nachrichten
Cantor Fitzgerald bestätigt "Overweight"-Rating für NewAmsterdam Pharma
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight
Guggenheim erhöht Kursziel für NewAmsterdam Pharma wegen beschleunigter EU-Markteinführung
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing
NewAmsterdam Pharma: EPS verfehlt Schätzungen um 0,23 $ - Umsatz schlechter als erwartet
NewAmsterdam Pharma earnings missed by $0.23, revenue fell short of estimates
NewAmsterdam erwartet EMA-Entscheidung zu Cholesterinsenker für zweite Jahreshälfte 2026
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026
NewAmsterdam Pharma: Leerink Partners hebt Kursziel auf 55 US-Dollar an
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners
Piper Sandler: Diese Biotech-Werte versprechen für 2026 transformatives Wachstum
Piper Sandler highlights commercial biotech names to own in 2026